In medical device development, few areas create more late-stage friction than verification and validation. Early-stage teams often assume these activities are just the final “testing phase” before regulatory submission. In reality, they are two distinct, resource-intensive workstreams that can determine whether a product moves forward on schedule or gets stuck in rework cycles.

Understanding the difference between verification and validation, and planning for both early, is one of the most important factors in predictable medtech development.

Verification vs validation in plain terms

Before diving into why teams underestimate the workload, it helps to clarify the distinction:

• Verification asks whether you built the device correctly according to specifications
• Validation asks whether you built the correct device for the intended use in the real world

Both are required under FDA design controls and ISO quality systems, but they serve very different purposes.

A simple way to think about it is:

• Verification is engineering correctness
• Validation is clinical and user reality

Why teams underestimate verification workload

Early-stage medtech teams often assume verification is a straightforward set of bench tests. In practice, it becomes a structured, traceable, and documentation-heavy process that scales with design complexity.

Common reasons verification gets underestimated:

1. Underestimating test depth required for traceability

In regulated development, every design input must map to at least one verification activity. That means:

• Each requirement needs a defined test method
• Each test needs documented acceptance criteria
• Each result needs traceable evidence

What looks like 10 product requirements can easily turn into 30 to 50 verification activities once decomposed properly.

2. Late realization of test fixture and protocol needs

Many teams assume testing is just “run the device and see if it works.” In reality, verification often requires:

• Custom test fixtures
• Calibrated measurement systems
• Defined environmental conditions
• Statistical sampling plans

Building these often takes longer than running the test itself.

3. Iteration loops from design instability

If design inputs are still evolving, verification becomes a moving target. Each design change can require:

• Rewriting test protocols
• Repeating previously completed tests
• Updating traceability documentation

This is one of the most common sources of timeline overruns in early programs.

Why validation is even more frequently underestimated

If verification is underestimated, validation is often misunderstood entirely.

Validation answers a fundamentally harder question: does the device work for real users in real conditions?

That introduces variability that engineering tests cannot fully simulate.

1. Human factors complexity is often delayed

Validation typically includes usability and human factors evaluation. Early teams often assume this is optional or lightweight.

In reality, it may involve:

• Formal usability studies
• Simulated clinical environments
• Task analysis with representative users
• Iterative design modifications based on user feedback

Human variability is one of the hardest variables to control in medtech validation.

2. Clinical environment differences from lab assumptions

Devices that perform well in controlled testing environments often behave differently in clinical settings due to:

• Time pressure on clinicians
• Workflow interruptions
• Environmental constraints
• Variability in patient conditions

Validation must capture these realities, which often requires multiple rounds of testing.

3. Reimbursement and stakeholder validation gaps

In many cases, validation extends beyond technical performance into adoption feasibility. That includes:

• Workflow integration
• Clinical utility perception
• Economic value justification

These factors are rarely considered during early design but become critical during commercialization.

The compounding effect of verification and validation overlap

One of the biggest sources of surprise is how tightly verification and validation are linked.

Changes uncovered during validation often force:

• Re-verification of affected requirements
• Updates to risk files under ISO 14971
• Revisions to design controls documentation
• Additional regulatory justification

This creates a cascading workload that teams rarely anticipate.

Why early-stage teams misjudge the workload

There are a few consistent patterns behind underestimation:

• Focus on prototyping success rather than regulated evidence generation
• Lack of early decomposition of requirements into testable elements
• Limited experience with FDA submission-level documentation
• Assuming “testing” is a single phase instead of a continuous process

In short, teams often design for functionality first and discover compliance requirements later.

How experienced medtech teams approach V&V differently

More experienced teams typically shift their approach early by:

• Defining verification plans alongside design inputs
• Building traceability from the beginning, not at the end
• Treating validation as iterative, not final-stage
• Accounting for human factors and clinical variability early in design cycles
• Aligning engineering and regulatory strategy continuously

This reduces rework and improves predictability in later development stages.